5d
Zacks.com on MSNVertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
VRTX stock has fared well in recent years ... amid label expansion and better price realization. Notably, 93% of the company’s total sales are generated by Trikafta/Kaftrio.
4d
Zacks.com on MSNVertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to NoteIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results